BioCentury
ARTICLE | Clinical News

Voraxaze glucarpidase: Compassionate use program data

June 11, 2012 7:00 AM UTC

Data from 492 patients with renal toxicity and delayed elimination of methotrexate treated under a U.S. and European compassionate use program during November 1993 to June 2009 showed that 50 U/kg IV Voraxaze reduced serum methotrexate levels from baseline at a median of 15 minutes post-treatment by 99%, which was maintained to hour 40. In 410 patients with grade >=2 renal impairment, 64% recovered to grade 0/1 at a median of 12.5 days. Voraxaze was well tolerated. Patients received 1-3 doses of Voraxaze at a median of 3 days after methotrexate treatment. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...